Association between vitamin D and uterine fibroids: a study protocol of an open-label, randomised controlled trial

Bo Sheng, Yizuo Song, Yi Liu, Chenchen Jiang, Xueqiong Zhu, Bo Sheng, Yizuo Song, Yi Liu, Chenchen Jiang, Xueqiong Zhu

Abstract

Introduction: Uterine fibroids are the most common pelvic benign tumour with no satisfactory long-term medical treatment. Recent studies have demonstrated that vitamin D significantly inhibited the growth of fibroids in vitro, vivo and a small-sample clinical trial. Therefore, the aim of this randomised clinical trial (RCT) is to evaluate whether supplementation with vitamin D could reduce the risk and inhibit the growth of uterine fibroids in reproductive stage women.

Methods and analysis: The open-label, RCT comprises two parts, including parts I and II. In part I, 2230 vitamin D deficiency or vitamin D insufficiency patients without uterine fibroids will be randomly assigned to two groups: intervention group (according to the level of serum 25-hydroxyvitamin D3, receive 1600 or 800 IU/day of vitamin D3 for 2 years) and control group (followed up at the same time points). By using gynaecological ultrasound examinations, the incidence of uterine fibroids will be employed to measure the outcome in different groups. In part II, 360 uterine fibroids patients with vitamin D deficiency or vitamin D insufficiency will be randomly assigned to intervention group or control group. According to the level of serum 25-hydroxyvitamin D3, 180 patients will receive 1600 or 800 IU/day of vitamin D3 for 2 years. Control group will receive regular follow-up. The outcome measure will be conducted using gynaecological ultrasound examinations to detect the growth of uterine fibroids in each group.

Ethics and dissemination: This study has been approved by the institutional review board of the Second Affiliated Hospital of Wenzhou Medical University (No. LCKY2018-35).

Trial registration numbers: NCT03586947 and NCT03584529.

Keywords: clinical trials; gynaecological oncology; protocols & guidelines.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart showing the steps of part Ⅰ in participant recruitment, treatment and analysis. UFs, uterine fibroids.
Figure 2
Figure 2
Flow chart showing the steps of part Ⅱ in participant recruitment, treatment and analysis.

References

    1. Stewart EA, Cookson CL, Gandolfo RA, et al. . Epidemiology of uterine fibroids: a systematic review. BJOG 2017;124:1501–12. 10.1111/1471-0528.14640
    1. Dagur G, Suh Y, Warren K, et al. . Urological complications of uterine leiomyoma: a review of literature. Int Urol Nephrol 2016;48:941–8. 10.1007/s11255-016-1248-5
    1. Vilos GA, Allaire C, Laberge P-Y, et al. . The management of uterine leiomyomas. J Obstet Gynaecol Can 2015;37:157–78. 10.1016/S1701-2163(15)30338-8
    1. Donnez J, Dolmans M-M. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016;22:665–86. 10.1093/humupd/dmw023
    1. Malik M, Britten J, Cox J, et al. . Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. Fertil Steril 2016;105:214–24. 10.1016/j.fertnstert.2015.09.006
    1. Ali M, Chaudhry ZT, Al-Hendy A. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov 2018;13:169–77. 10.1080/17460441.2018.1417381
    1. Shen Q, Hua Y, Jiang W, et al. . Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 2013;100:1722–6. 10.1016/j.fertnstert.2013.08.039
    1. Liu C, Lu Q, Qu H, et al. . Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial. Medicine 2017;96:e6124. 10.1097/MD.0000000000006124
    1. Shen Q, Shu L, Luo H, et al. . The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas. Medicine 2017;96:e6680. 10.1097/MD.0000000000006680
    1. Commandeur AE, Styer AK, Teixeira JM. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update 2015;21:593–615. 10.1093/humupd/dmv030
    1. Chen W, Ohara N, Wang J, et al. . A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006;91:1296–304. 10.1210/jc.2005-2379
    1. Murphy AA, Kettel LM, Morales AJ, et al. . Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513–7. 10.1210/jcem.76.2.8432797
    1. Murji A, Whitaker L, Chow TL, et al. . Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017;4:CD010770. 10.1002/14651858.CD010770.pub2
    1. Melis GB, Neri M, Piras B, et al. . Vilaprisan for treating uterine fibroids. Expert Opin Investig Drugs 2018;27:497–505. 10.1080/13543784.2018.1471134
    1. Parazzini F, Di Martino M, Candiani M, et al. . Dietary components and uterine leiomyomas: a review of published data. Nutr Cancer 2015;67:569–79. 10.1080/01635581.2015.1015746
    1. Ciebiera M, Łukaszuk K, Męczekalski B, et al. . Alternative oral agents in prophylaxis and therapy of uterine Fibroids-An up-to-date review. Int J Mol Sci 2017;1810.3390/ijms18122586
    1. Baird DD, Hill MC, Schectman JM, et al. . Vitamin D and the risk of uterine fibroids. Epidemiology 2013;24:447–53. 10.1097/EDE.0b013e31828acca0
    1. Ciebiera M, Włodarczyk M, Słabuszewska-Jóźwiak A, et al. . Influence of vitamin D and transforming growth factor β3 serum concentrations, obesity, and family history on the risk for uterine fibroids. Fertil Steril 2016;106:1787–92. 10.1016/j.fertnstert.2016.09.007
    1. Bläuer M, Rovio PH, Ylikomi T, et al. . Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril 2009;91:1919–25. 10.1016/j.fertnstert.2008.02.136
    1. Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2011;96:E754–62. 10.1210/jc.2010-2131
    1. Halder SK, Sharan C, Al-Hendy A. 1,25-Dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod 2012;86:116. 10.1095/biolreprod.111.098145
    1. Halder SK, Sharan C, Al-Hendy O, et al. . Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci 2014;21:1108–19. 10.1177/1933719114537721
    1. Corachán A, Ferrero H, Aguilar A, et al. . Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway. Fertil Steril 2019;111:397–407. 10.1016/j.fertnstert.2018.10.008
    1. Corachán A, Ferrero H, Escrig J, et al. . Long-term vitamin D treatment decreases human uterine leiomyoma size in a xenograft animal model. Fertil Steril 2020;113:205–16. 10.1016/j.fertnstert.2019.09.018
    1. Li S, Chen B, Sheng B, et al. . The associations between serum vitamin D, calcium and uterine fibroids in Chinese women: a case-controlled study. J Int Med Res 2020;48:300060520923492. 10.1177/0300060520923492
    1. Ciavattini A, Delli Carpini G, Serri M, et al. . Hypovitaminosis D and “small burden” uterine fibroids: Opportunity for a vitamin D supplementation. Medicine 2016;95:e5698. 10.1097/MD.0000000000005698
    1. Arjeh S, Darsareh F, Asl ZA, et al. . Effect of oral consumption of vitamin D on uterine fibroids: a randomized clinical trial. Complement Ther Clin Pract 2020;39:101159. 10.1016/j.ctcp.2020.101159
    1. Brakta S, Diamond JS, Al-Hendy A, et al. . Role of vitamin D in uterine fibroid biology. Fertil Steril 2015;104:698–706. 10.1016/j.fertnstert.2015.05.031
    1. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis. Mol Cell Endocrinol 2017;453:36–45. 10.1016/j.mce.2017.04.008
    1. Faridi KF, Lupton JR, Martin SS, et al. . Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk. Arch Med Sci 2017;13:732–7. 10.5114/aoms.2017.68237
    1. Akoh CC, Pressman EK, Cooper E, et al. . Low vitamin D is associated with infections and proinflammatory cytokines during pregnancy. Reprod Sci 2018;25:414–23. 10.1177/1933719117715124
    1. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. . Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911–30. 10.1210/jc.2011-0385
    1. Alzaman NS, Dawson-Hughes B, Nelson J, et al. . Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation. Am J Clin Nutr 2016;104:205–14. 10.3945/ajcn.115.129478
    1. Powe CE, Evans MK, Wenger J, et al. . Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013;369:1991–2000. 10.1056/NEJMoa1306357
    1. Aspray TJ, Bowring C, Fraser W, et al. . National osteoporosis Society vitamin D guideline summary. Age Ageing 2014;43:592–5. 10.1093/ageing/afu093
    1. Liao X, Zhang Z, Zhang H, et al. . Application guideline for vitamin D and bone health in adult Chinese (2014 standard edition). Chinese Journal of Osteoporosis 2014;20:1011–30.
    1. Barry EL, Rees JR, Peacock JL, et al. . Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. J Clin Endocrinol Metab 2014;99:E2133–7. 10.1210/jc.2014-1389
    1. de Boer IH, Zelnick LR, Ruzinski J, et al. . Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial. JAMA 2019;322:1899. 10.1001/jama.2019.17380
    1. Burt LA, Billington EO, Rose MS, et al. . Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA 2019;322:736–45. 10.1001/jama.2019.11889
    1. Urashima M, Ohdaira H, Akutsu T, et al. . Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial. JAMA 2019;321:1361–9. 10.1001/jama.2019.2210
    1. Scragg R, Khaw K-T, Toop L, et al. . Monthly high-dose vitamin D supplementation and cancer risk: a post hoc analysis of the vitamin D assessment randomized clinical trial. JAMA Oncol 2018;4:e182178. 10.1001/jamaoncol.2018.2178
    1. Aglipay M, Birken CS, Parkin PC, et al. . Effect of high-dose vs standard-dose Wintertime vitamin D supplementation on viral upper respiratory tract infections in young healthy children. JAMA 2017;318:245–54. 10.1001/jama.2017.8708
    1. Zittermann A, Ernst JB, Prokop S, et al. . Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. Eur Heart J 2017;38:2279–86. 10.1093/eurheartj/ehx235
    1. Lappe J, Watson P, Travers-Gustafson D, et al. . Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA 2017;317:1234–43. 10.1001/jama.2017.2115
    1. Arora P, Song Y, Dusek J, et al. . Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation 2015;131:254–62. 10.1161/CIRCULATIONAHA.114.011732
    1. Rusińska A, Płudowski P, Walczak M, et al. . Vitamin D supplementation guidelines for general population and groups at risk of vitamin D deficiency in Poland-Recommendations of the Polish Society of pediatric endocrinology and diabetes and the expert panel with participation of national specialist consultants and representatives of scientific Societies-2018 update. Front Endocrinol 2018;9:246. 10.3389/fendo.2018.00246

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel